Logo Lanfrica

Optimizing Dose and Limiting Laboratory Monitoring of Hydroxyurea in Africa: Design of the Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSH-UP) Trial

Domaine:

healthcare
Créateur:
PatChrMarRui
Éditeur:
Ame
Hôte:

Similaires

Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience

Introduction: Realizing Effectiveness Across Continents with Hydroxyurea (REACH, NCT01966731) is an

Randomized Controlled Trial of Fixed Low-Vs Moderate-Dose Hydroxyurea for Primary Stroke Prevention in Sub-Saharan Africa: Final Results of the Spring Trial

Introduction: In children with sickle cell anemia (SCA) without transcranial Doppler (TCD) screening

Hydroxyurea pharmacokinetics and precision dosing in low-resource settings

Introduction: Hydroxyurea is effective disease-modifying treatment for sickle cell anemia (SCA). Es

sickle-in-africa/outcome-of-hydroxyurea-use

R scripts for the Frontiers publication *Outcome of Hydroxyurea Use in SCD and Evaluation of Patient

Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa

Abstract Hydroxyurea is a potent and safe disease-modifying therapy for sickle cell

Optimizing Hydroxyurea Dosing in Sickle Cell Anemia: The Uganda MTD Study

Introduction. Hydroxyurea treatment has proven safety, feasibility, and efficacy for children with s